FDA Inspection
K.C. Pharmaceuticals, IncK.C. Pharmaceuticals, Inc – FDA Inspection, Aug 28, 2024
Record Details
This FDA Inspection record concerns K.C. Pharmaceuticals, Inc, with an inspection on August 28, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 4d2997fd-981a-47b9-b559-199031f88ad1
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1247201
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
6- 21 CFR 211.122(d)Label storage access limited to authorized personnel
- 21 CFR 211.194(a)(8)Second person sign off
- 21 CFR 211.113(b)Validation lacking for sterile drug products
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.166(a)Written program not followed
- 21 CFR 211.100(a)Absence of Written Procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of K.C. Pharmaceuticals, Inc
10| Date | Classification | Office | Project area |
|---|---|---|---|
| February 13, 2026 | Not classified | Los Angeles District Office | Drug Quality Assurance |
| February 13, 2023 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 30, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| November 16, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 19, 2015 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for K.C. Pharmaceuticals, Inc
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.